Clinical trial
A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)
NCT04752566 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 8, 2021
- Completion date
- August 3, 2022
- Enrollment
- 57 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.